EP0590152A1 - Peptides antagonistes de la tachykonine - Google Patents

Peptides antagonistes de la tachykonine

Info

Publication number
EP0590152A1
EP0590152A1 EP92913210A EP92913210A EP0590152A1 EP 0590152 A1 EP0590152 A1 EP 0590152A1 EP 92913210 A EP92913210 A EP 92913210A EP 92913210 A EP92913210 A EP 92913210A EP 0590152 A1 EP0590152 A1 EP 0590152A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
compound
carboxy
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92913210A
Other languages
German (de)
English (en)
Inventor
Masaaki 4-12 Nakasakurazuka 5-Chome Matsuo
Daijiro 20-11 Kindacho 2-Chome Hagiwara
Hiroshi 86 Jodojinishidacho Sakyo-Ku Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of EP0590152A1 publication Critical patent/EP0590152A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to new peptide
  • tachykinin antagonism especially substance P antagonism, neurokinin A antagonism, neurokinin .B antagonism, and the like, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same as a medicament.
  • One object of the present invention is to provide new and useful peptide compounds and pharmaceutically
  • tachykinin antagonism especially substance P antagonism, neurokinin A antagonism,
  • neurokinin B antagonism and the like.
  • Another object of the present invention is to provide processes for the preparation of said peptide compounds and salts thereof.
  • a further object of the present invention is to provide a pharmaceutical composition
  • a pharmaceutical composition comprising, as an active ingredient, said peptide compounds and
  • Still further object of the present invention is to provide a use of said peptide compound or a
  • tachykinin antagonist especially substance P antagonist, neurokinin A antagonist or neurokinin B antagonist, useful for treating or preventing tachykinin mediated diseases, for example, respiratory diseases such as asthma, bronchitis, rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like; cutaneous diseases such as contact
  • dermatitis atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like
  • inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like
  • pains or aches e.g., migraine, headache, toothache, cancerous pain, back pain, etc.
  • the like in human being or animals e.g., migraine, headache, toothache, cancerous pain, back pain, etc.
  • the object compounds of the present invention can be represented by the following general formula (I).
  • R 1 is lower alkyl, aryl, ar(lower)alkyl
  • Z is O, S or NH
  • R 2 is hydrogen or lower alkyl
  • R 3 is hydrogen or suitable substituent
  • R 4 is lower alkyl which may have suitable
  • R 5 is ar( lower)alkyl which may have suitable
  • R 4 and R 5 are linked together to form
  • A is an amino acid residue which may have
  • Y is bond, lower alkylene, lower alkenylene
  • R 1 is aryl, or a group of the formula :
  • Z is O or N-R 6 a ,
  • R 6 a is hydrogen or lower
  • R 2 is hydrogen
  • R 4 is lower alkyl which may have suitable
  • R 5 is ar(lower)alkyl which may have suitable substituent(s),
  • A is group of the formula :
  • R 7 is hydoxy or lower alkoxy
  • Y is bond or lower alkenylene
  • R 3 is suitable substituent.
  • the new peptide compounds (I) can be prepared by processes which are illustrated in the following schemes.
  • R 1 , R 2 , R 3 , R 4 , R 5 , A, X and Y are each as defined above,
  • R 4 a is protected carboxy (lower) alkyl
  • R 4 b is carboxy (lower) alkyl
  • R 6 b is protected carboxy (lower) alkyl or
  • R 6 c is carboxy (lower) alkyl or
  • R 6 b is amino (lower) alkyl
  • R 6 e is guanidino (lower) alkyl
  • R 8 is hydrogen or halogen
  • a 1 is an amino acid residue containing an amino
  • a 2 is an amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid residue containing a protected amino acid
  • a 3 is an amino acid residue containing a sulfonyloxy which has a suitable substituent
  • a 4 is an amino acid residue containing an azido
  • a 5 is an amino acid residue containing an amino
  • Ma is an alkaline metal.
  • amino acid, peptides, protective groups, condensing agents, etc. are indicated by the abbreviations according to the IUPAC-IUB (Commission on Biological Nomenclature) which are in common use in the field of art.
  • amino acids and their residues when shown by such abbreviations are meant to be L-configured compounds and residues.
  • Suitable pharmaceutically acceptable salts of the starting and object compound are conventional non-toxic salt and include an acid addition salt such as an organic acid salt (e.g. acetate, trifluoroacetate, maleate. tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g.
  • an organic acid salt e.g. acetate, trifluoroacetate, maleate. tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.
  • an inorganic acid salt e.g.
  • hydrochloride hydrobromide, hydriodide, sulfate, nitrate, phosphate, etc.
  • a salt with an amino acid e.g.
  • arginine aspartic acid, glutamic acid, etc.
  • a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt,
  • dicyclohexylamine salt N,N'-dibenzylethylenediamine salt, etc.), or the like.
  • Suitable “lower alkyl” may include a straight or branched one such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like, in which the most preferred one is methyl.
  • Suitable "aryl” and the aryl moiety of “arylamino” may include phenyl, tolyl, xylyl, mesityl, cumenyl, naphtyl, and the like, in which the preferred one is
  • Suitable "ar(lower)alkyl” may include mono- or di- or triphenyK lower) alkyl (e.g. trityl, benzhydryl, benzyl, phenethy1, etc.), and the like.
  • Suitable "lower alkylene” is one having 1 to 6 carbon atom(s) and may include methylene, ethylene, trimethylene, propylene, tetramethylene, methyltrimethylene,
  • hexamethylene and the like, in which the preferred one is methylene, ethylene or trimethylene.
  • Suitable "lower alkenylene” is one having 2 to 6 carbon atom(s) and may include vinylene, propenylene, and the like, in which the preferred one is vinylene.
  • Suitable “lower alkylimino” may include methylimino, ethylimino, and the like.
  • an amino acid residue means a bivalent residue derived from an amino acid, and such amino acid may be glycine (Gly), D- or L- alanine (Ala), ⁇ -alanine ( ⁇ Ala), D- or L- valine (Val), D- or L- leucine (Leu), D- or L- isoleucine (lie), D- or L- serine (Ser), D- or L- threonine (Thr), D- or L- cysteine (Cys), D- or L- methionine (Met) , D- or L- phenylalanine (Phe) , D- or L-tryptophan (Trp), D- or L- tyrosine (Tyr), D- or L- proline (Pro), D- or L- didehydroproline ( ⁇ Pro) such as 3 ,4-didehydroproline ( ⁇ ( 3 , 4)Pro) , D- or L- hydroxyproline (Pro(OH
  • carbamoyl lower alkanoyl (e.g., formyl, acetyl, etc.), lower alkoxycarbonyl (e.g.,t-butoxycarbonyl, etc.), trihalo(lower) alkoxycarbonyl (e.g.
  • alkylsulfonyl e.g., mesyl ethylsulfonyl, etc.
  • lower alkoxalyl e.g., methoxyalyl, ethoxyalyl, etc.
  • arylsulfonyl e.g., phenylsulfonyl, tolylsulfonyl, etc.
  • haloar( lower) alkoxycarbonyl e.g., o-chlorobenzyloxy- carbonyl, etc.
  • carboxy(lower)alkanoyl e.g.,
  • alkoxycarbonyl- ⁇ -alanyl e.g.,
  • N,N-di(lower) alkylamino(lower)alkanoyl e.g., N,N-di(lower) alkylamino(lower)alkanoyl
  • amino(lower)alkanoyl e.g., aminoacetyl, aminopropionyl, etc.
  • N-ar(lower)alkoxycarbonylamino(lower)alkanoyl e.g, N-benzyloxycarbonylaminoacetyl, etc.
  • threonyl N-lower alkoxycarbonylthreonyl (e.g. N-t-butoxycarbonylthreonyl, etc.)
  • N-lower alkanoylthreonyl e.g., N-acetylthreonyl, etc.
  • alkoxycarbonylamino(lower)alkanoyl e.g.,
  • carboxymethyl, etc. protected carboxy (lower) alkyl such as esterified carboxy (lower) alkyl (e.g.
  • morpholino glycino amide, threonino amide, N'-glutamino N-lower alkylamide (e.g., N'-glutamino N-t-butylamide, etc.), di ⁇ lower)alkylamino (e.g.
  • Suitable “carboxy(lower)alkyl” may include
  • Suitable "protected carboxy(lower)alkyl” means the above-mentioned carboxy(lower)alkyl, in which the carboxy group is protected by a conventional protective group such as esterified carboxy group.
  • Preferred example of the ester moiety thereof may include lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, tert-butyl ester, etc.), and the like.
  • suitable substituent(s)" may include carbamoyl(lower)alkyl (e.g., carbamoylmethyl, carbamoylethyl, carbamoylpropyl, etc.), carbamoyl(lower)alkyl having suitable
  • substituent(s) such as lower alkylcarbamoyl(lower)alkyl (e.g., methylcarbamoylmethyl, ethylcarbamoylmethyl, etc.), amino(lower)alkylcarbamoyl(lower)alkyl (e.g.,
  • aminomethylcarbamoylmethyl aminoethylcarbamoylmethyl, etc.
  • lower alkylamino(lower)alkylcarbamoyl(lower)alkyl e.g., dimethylaminomethylcarbamoylmethyl
  • substituent(s) may include a conventional group, which is used in the field of art such as lower alkyl,
  • lower alkylamino(lower)alkyl e.g. dimethylaminomethyl, dimethylaminoethyl, etc.
  • hydroxy(lower)alkyl e.g., hydroxymethyl, hydroxyethyl, etc.
  • hydroxy(lower)alkyl such as acyloxy(lower)alkyl (e.g.
  • halo(lower)alkyl e.g.
  • pyrrolidinyl(lower)alkyl e.g. pyrrolidin-1-ylethyl, etc.
  • pyrrolidin-1-ylethyl e.g. pyrrolidin-1-ylethyl, etc.
  • Suitable "an amino acid residue containing an amino, a hydroxy and/or a carboxy" may include a bivalent residue of an amino acid such as Pro(40H), Ser, Thr, Tyr, and the like.
  • protected amino, a protected hydroxy and/or a protected carboxy means the above-mentioned group, in which the amino, hydroxy and/or carboxy is protected by a
  • arylsulfonyl e.g., phenylsulfonyl, tolylsulfonyl, etc.
  • lower alkoxycarbonyl(lower)alkyl e.g., methoxycarbonylmethyl, ethoxycarbonylmethyl, etc.
  • Suitable “pyridyKlower)alkyl” may include 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, and the like.
  • Suitable group of the formula : in which R 4 and R 5 are linked together to form benzene-condensed lower alkylene, may include 1-indolinyl, 2-isoindolinyl,
  • Suitable "hydroxy(lower)alkyl” may include
  • Suitable "protected hydroxy(lower)alkyl” means the above-mentioned hydroxy(lower)alky1, in which the hydroxy group is protected by a conventional protective group such as acyl (e.g. acetyl, etc.), and may include
  • Suitable "amino protective group” may be a
  • acyl such as lower alkanoyl (e.g. formyl, acetyl,
  • propionyl butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, etc.
  • lower alkoxycarbonyl e.g.
  • alkanesulfonyl e.g. methanesulfonyl, ethanesulfonyl, etc. and the like.
  • Suitable “carboxy(lower)alkoxy” may include
  • Suitable "protected carboxy(lower)alkoxy” means the above-mentioned carboxy(lower)alkoxy, in which the carboxy group is protected by a conventional protective group such as esterified carboxy group.
  • Preferred example of the ester moiety thereof may include lower alkyl ester (e.g. methyl ester, ethyl ester, propyl ester, tert-butyl ester, etc. and the like.
  • Suitable "lower alkoxy” may include straight or branched one such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, hexyloxy, and the like.
  • sulfonyloxy which has a suitable substituent means a bivalent residue derived, from an amino acid containing sulfonyloxy which has a suitable substituent, in which "sulfonyloxy which has a suitable substituent" may include lower alkylsulfonyloxy (e.g., methylsulfonyloxy,
  • arylsulfonyloxy e.g., phenylsulfonyloxy, tolylsulfonyloxy, etc.
  • arylsulfonyloxy e.g., phenylsulfonyloxy, tolylsulfonyloxy, etc.
  • Suitable "an amino acid residue containing an azido" may include a bivalent residue of an amino acid such as Pro( 4N 3 ) , and the like.
  • Suitable "an amino acid residue containing an amino” may include a bivalent residue of an amino acid such as Pro(4NH 2 ), and the like.
  • Suitable “amino (lower) alkyl” may include aminomethyl, aminoethyl, aminopropyl, and the like.
  • Suitable "protected amino(lower) alkyl” means the above-mentioned amino (lower) alkyl, in which the amino group is protected by a conventional protective group such as acylamino group.
  • Preferred example of the acyl moiety thereof may include lower alkoxycarbonyl (e.g.
  • Suitable “guanidino (lower) alkyl” may include
  • Suitable "halogen” may include chloro, fluoro,
  • Suitable "alkaline metal” may include sodium,
  • Suitable substituent on R moiety may include a.
  • lower alkyl which may have suitable substituent(s), amino protective group, each as defined above, hydroxy, halogen (e.g. fluoro, chloro, etc.), lower alkoxy (e.g. methoxy, butoxy, etc.),
  • N,N-di(lower)alkylamino e.g. dimethylamino, etc.
  • lower alkoxycarbonyl e.g. methoxycarbonyl, t-butoxycarbonyl, etc.
  • lower alkyleneamino(lower)alkyl e.g. pyrrolidin-1-ylethyl, etc.
  • Suitable substituent on R 3 moiety may include a conventional group, which is used in the field of amino acid and peptide chemistry, such as lower alkyl which may have suitable substituent(s), carboxy(lower)alkoxy, protected carboxy(lower)alkoxy, each as defined above, halogen (e.g. fluoro, chloro, etc.), lower alkoxy (e.g. methoxy, butoxy, etc.), nitro, amino, protected amino, in which amino protective group is as defined above, and the like.
  • R 1 , R 2 , R 3 , R 4 , R 5 , A and Y are as follows.
  • R' is di(lower) alkoxyphenyl, mono-or di-or triphenyl- (lower) alkyl which may have lower alkoxy, indolinyl, pyridyl, or a group of the formula :
  • R 6 is lower alkyl, di (lower)alkylamino-
  • R 8 is hydrogen or halogen
  • R 2 is hydrogen or lower alkyl
  • R 3 is lower alkyl or halogen
  • R 4 is lower alkyl, carboxy(lower)alkyl or esterified
  • R 5 is mono-or di-or triphenyl(lower)alkyl or pyridyl(lower)-alkyl, A is a bivalent residue derived from an amino acid
  • substituents such as hydroxyproline, glycine, serine, methionine, lysine, histidine, glutamine, thioproline and aminoproline, whose side chains may be substituted by the substituent selected from the group consisting of lower alkoxycarbonyl, carboxy(lower)alkyl,
  • Y is bond, lower alkylene, lower alkenylene or lower alkylimino.
  • R 1 , R 2 , R 3 , R 4 , R 5 , A and Y are as follows.
  • R' is a group of the formula :
  • R 6 is lower alkyl
  • R 8 is hydrogen
  • R 2 is hydrogen
  • R 3 is lower alkyl or halogen
  • R 4 is lower alkyl
  • R 5 is phenyl(lower)alkyl
  • A is hydroxyproline
  • R 1 , R 2 , R 3 , R 4 , R 5 , A and Y are bond. Also, the preferred embodiments of R 1 , R 2 , R 3 , R 4 , R 5 , A and Y are as follows.
  • R 1 is di(lower)alkoxyphenyl, mono-or di-or triphemyl (lower)- alkyl which may have lower alkoxy, indolinyl, pyridyl, or a group of the formula :
  • R 6 is lower alkyl, di(lower)alkylamino- (lower)alkyl, pyrrolidinyl(lower)alkyl, carboxy(lower)alkyl, esterified carboxy- (lower)alkyl, amino(lower) alkyl, guanidino(lower)alkyl, pyridyl (lower)alkyl or acylamino(lower)alkyl, and
  • R 8 is hydrogen or halogen
  • R 2 is hydrogen or lower alkyl
  • R 3 is hydrogen
  • R 4 is lower alkyl, carboxy(lower)alkyl or esterified
  • R 5 is mono-or di-or triphenyl(lower)alkyl
  • A is a bivalent residue derived from an amino acid
  • hydroxyproline which may have suitable substituent such as glycine, serine, methionine, lysine, histidine, glutamine, thioproline and
  • aminoproline whose side chains may be substituted by the substituent selected from the group consisting of lower alkoxycarbonyl, carboxy( lower)alkyl, esterified carboxy(lower)alkyl and lower alkylsulfonyl, and
  • Y is bond, lower alkylene, lower alkenylene or lower
  • R 1 , R 2 , R 3 , R 4 , R 5 , A and Y are as follows.
  • R 1 is di(lower)alkoxy ⁇ henyl, mono-or di-or triphemyl (lower)- alkyl which may have lower alkoxy, indolinyl, pyridyl, or a group of the formula :
  • R 6 is di(lower)alkylamino(lower)alkyl
  • pyrrolidinyl(lower)alkyl carboxy(lower)alkyl, esterified carboxy(lower)alkyl, amino(lower)- alkyl, guanidino(lower)alkyl, pyridyl(lower)- alkyl or acylamino(lower)alkyl, and R 8 is hydrogen or halogen,
  • R a is hydrogen or lower alkyl
  • R 3 is hydrogen
  • R 4 is lower alkyl, carboxy(lower)alkyl or esterified
  • R 5 is mono-or di-or triphenyl(lower)alkyl
  • A is a bivalent residue derived from hydroxyproline which
  • Y is bond, lower alkylene, lower alkenylene or lower
  • the object compound (I) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the amino group or a salt thereof with the compound (III) or its reactive derivative at the carboxy group or a salt thereof.
  • Suitable reactive derivative at the amino group of the compound (II) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (II) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (II) with a silyl compound such as bis(trimethylsilyl)acetamide, mono(trimethylsyliy acetamide, bis( trimethylsilyl)urea or the like; a derivative formed by reaction of the compound (II) with phosphorus trichloride or phosgene, and the like.
  • Suitable salts of the compound (II) and its reactive derivative can be referred to the ones as exemplified for the compound (I).
  • Suitable reactive derivative at the carboxy group of the compound (III) may include an acid halide, an acid anhydride, an activated amide, an activated ester, and the like.
  • Suitable examples of the reactive derivatives may be an acid chloride; an acid azide; a mixed acid anhydride within acid such as substituted phosphoric acid [e.g.
  • halogenated phosphoric acid, etc. dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, sulfuric acid, sulfonic acid [e.g. methanesulfonic acid, etc.], aliphatic carboxylic acid [e.g. acetic acid, propionic acid, butyric acid, isobutyric acid, pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.] or aromatic carboxylic acid [e.g. benzoic acid, etc.]; a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole,
  • dimethylpyrazole triazole or tetrazole
  • an activated ester e.g. cyanomethyl ester, rnethoxymethyl ester, dimethyliminomethyl 3 2 ester, vinyl ester,
  • N-hydroxy compound e.g. N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide,
  • N-hydroxyphthalimide 1-hydroxy-1H-benzotriazole, etc.]
  • These reactive derivatives can optionally be selected from them according to the kind of the
  • Suitable salts of the compound (III) and its reactive derivative may be a base salt such as an alkali metal salt [e.g. sodium salt, potassium salt, etc.], an alkaline earth metal salt [e.g. calcium salt, magnesium salt, etc.], an ammonium salt, an organic base salt [e.g.
  • trimethylamine salt triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt,
  • the reaction is usually carried out in a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform. methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
  • a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile, chloroform. methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely influence the reaction.
  • a conventional solvent such as water, alcohol [e.g. methanol, ethanol, etc.], acetone, dioxane, acetonitrile,
  • a conventional condensing agent such as N,N' -dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide;
  • N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide N,N' -diethylcarbodiimide, N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide;
  • 1-alkoxy-l-chloroethylene 1-alkoxy-l-chloroethylene; trialkyl phosphite; ethyl polyphosphate; isopropyl polyphosphate; phosphorus
  • triphenylphosphine 2-ethyl-7-hydroxybenzisoxazolium salt
  • reaction may also be carried out in the presence of an inorganic or organic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine,
  • N-(lower)alkylmorpholine N,N-di(lower)alkylbenzylamine, or the like.
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling to warming.
  • the object compound (I) or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the amino group or a salt thereof with the compound (V) or its reactive derivative at the carboxy group or a salt thereof.
  • Suitable salts of the compound (IV) and its reactive derivative can be referred to the ones as exemplified for the compound (II).
  • Suitable salts of the compound (V) and its reactive derivative can be referred to the ones as exemplified for the compound (III).
  • This reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. reactive derivatives, solvents, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 1.
  • reaction mode and reaction conditions e.g. reactive derivatives, solvents, reaction temperature, etc.
  • the object compound (I-b) or a salt thereof can be prepared by subjecting the compound (I-a) or a salt thereof to elimination reaction of the amino, hydroxy and/or carboxy protective group.
  • Suitable base may include, for example, an inorganic base such as alkali metal hydroxide (e.g. sodium
  • alkaline earth metal hydroxide e.g. magnesium hydroxide, calcium
  • alkali metal carbonate e.g. sodium carbonate, potassium carbonate, etc.
  • alkaline earth metal carbonate e.g. magnesium carbonate, calcium
  • alkali metal bicarbonate e.g. sodium bicarbonate, potassium bicarbonate, etc.
  • alkali metal acetate e.g. sodium acetate, potassium acetate, etc.
  • alkaline earth metal phosphate e.g. magnesium phosphate, calcium phosphate, etc.
  • alkali metal hydrogen phosphate e.g. disodium hydrogen phosphate, dipotassium hydrogen phosphate, etc.
  • an organic base such as trialkylamine (e.g. trimethylaminev triethylamine, etc.), picoline, N-methylpyrrolidine, N-methylmorpholine,
  • Suitable acid may include an organic acid (e.g.
  • formic acid acetic acid, propionic acid, etc.
  • an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, etc.
  • the present hydrolysis is usually carried out in an organic solvent, water, or a mixed solvent thereof.
  • the reaction temperature is not critical, and it may suitably be selected in accordance with the kind of the carboxyprotective group and the elimination method.
  • the elimination using Lewis acid is carried out by reacting the compound (I-a) or a salt thereof with Lewis acid such as boron trihalide (e.g. boron trichloride, boron trifluoride, etc.), titanium tetrahalide (e.g. titanium tetrachloride, titanium tetrabromide, etc.), tin tetrahalide (e.g. tin tetrachloride, tin tetrabromide, etc.), aluminum halide (e.g. aluminum chloride, aluminum bromide, etc.), trihaloacetic acid (e.g. trichloroacetic acid, trifluoroacetic acid, etc.) or the like.
  • Lewis acid such as boron trihalide (e.g. boron trichloride, boron trifluoride, etc.), titanium tetrahalide (e.g. titanium tetrachloride, titanium tetrabromide,
  • This elimination reaction is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane, nitroethane, etc.), alkylene halide (e.g. methylene chloride, ethylene chloride, etc.), diethyl ether, carbon disulfide or any other solvent which does not adversely affect the cation trapping agents (e.g. anisole, phenol, etc.) and is usually carried out in a solvent such as nitroalkane (e.g. nitromethane, nitroethane, etc.), alkylene halide (e.g. methylene chloride, ethylene chloride, etc.), diethyl ether, carbon disulfide or any other solvent which does not adversely affect the nitroalkane (e.g. nitromethane, nitroethane, etc.), alkylene halide (e.
  • the reduction elimination can be applied preferably for elimination of the protective group such as
  • halo(lower)alkyl e.g. 2-iodoethyl, 2,2,2-trichloroethyl, etc.
  • ar(lower)alkyl e.g. benzyl, etc.
  • the reduction method applicable for the elimination reacting may include, for example, reduction by using a combination of a metal (e.g. zinc , zinc amalgam, etc. ) or a salt of chromium compound (e.g. chromous chloride, chromous acetate, etc.) and an organic or an inorganic acid (e.g. acetic acid, propionic acid, hydrochloric acid, etc.); and conventional catalytic reduction in the
  • the reaction temperature is not critical, and the reaction is usually carried out under cooling, at ambient temperature or under warming.
  • the object compound (I-d) or a salt thereof can be prepared by subjecting the compound (I-C) or a salt thereof to elimination reaction of the carboxy or amino, protective group.
  • This reaction can be carried out in substantially the same manner as Process 3, and therefore the reaction mode and reaction conditions [e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.] of this reaction are to be referred to those as explained in Process 3.
  • reaction mode and reaction conditions e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.
  • the object compound (1-3. or a salt thereof can be prepared by subjecting the compound (I-b) or its reactive derivative at the amino, hydroxy and/or carboxy group or a salt thereof to introduction reaction of the amino, hydroxy and/or carboxy protective group.
  • reaction can be carried out in substantially the same manner as Process 1, and therefore the reaction mode and reaction conditions [e.g. solvents, reaction
  • the present reaction includes, within its scope, the case that the amino group on R 1 is reacted during the reaction or at the post-treating step of the present process.
  • the compound (I-f) or a salt thereof can be prepared by reactin ⁇ the compound ( I-e) or a salt thereof with the compound (VI).
  • the reaction is usually carried out in a conventional solvent such as dimethyl sulfoxide or any other solvent which does not adversely influence the reaction.
  • the object compound (I-g) or a salt thereof can be prepared by subjecting the compound (I-f) or a salt thereof to hydrogenation. This reaction is usually carried out in the presence of triphenylphosphine, palladium on carbon, or the like.
  • the reaction is usually carried out in a conventional solvent such as alcohol (e.g., methanol, ethanol, etc.), or any other solvent which does not adversely influence the reaction.
  • a conventional solvent such as alcohol (e.g., methanol, ethanol, etc.), or any other solvent which does not adversely influence the reaction.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the object compound (I-i) or a salt thereof can be prepared by subjecting the compound (I-h) or a salt thereof to elimination reaction of the carboxy protective group.
  • This reaction can be carried out in substantially the same manner as Process 3, and therefore the reaction mode and reaction conditions [e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.] of this reaction are. to be referred to those as explained in Process 3.
  • reaction mode and reaction conditions e.g. bases, acids, reducing agents, catalysts, solvents, reaction temperature, etc.
  • the object compound (I-k) or a salt thereof can be prepared by subjecting the compound (I-f) or a salt thereof to introduction reaction of amidino group.
  • This reaction is usually carried out in the presence of introducing agent of amidino group such as
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.
  • the compound (I) and the other compounds may include one or more stereoisomers due to asymmetric carbon atoms, and all of such isomers and mixture thereof are included within the scope of this invention.
  • the object compounds (I) and pharmaceutically acceptable salt thereof have pharmacological activities such as tachykinin antagonism, especially substance P antagonism, neurokinin A antagonism or neurokinin B antagonism, and therefore are useful for treating or preventing tachykinin mediated diseases, particularly substance P mediated diseases, for example, respiratory diseases such as asthma, bronchitis rhinitis, cough, expectoration, and the like; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, and the like;
  • cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis, and the like; inflammatory diseases such as rheumatoid arthritis, osteoarthritis, and the like; pains or aches (e.g. migraine, headache, toothache, cancerous pain, back pain, etc.); and the like.
  • object compounds (I) of the present invention are useful for treating or preventing ophthalmic diseases such as glaucoma, uveitis, and the like; gastrointestinal diseases such as ulcer, ulcerative colitis, irritable bowel syndrome, food
  • inflammatory diseases such as nephritis, and the like
  • circulatory diseases such as hypertension, angina pectoris, cardiac failure
  • thrombosis and the like; epilepsy; spastic paralysis; pollakiuria; dementia; Alzheimer's diseases;
  • the compounds (I) and pharmaceutically acceptable salts thereof of the present invention can be used in a form of pharmaceutical
  • compositions may be capsules, tablets, dragees, granules, solution, suspension, emulsion, or the like. If desired, there may be included in these preparation, auxiliary substances, stabilizing agents, wetting or emulsifying agents, buffers and other commonly used additives.
  • the dosage of the compounds (I) will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg,
  • 100 mg, 250 mg, 500 mg and 1000 mg of the compound (I) may be effective for treating asthma and the like.
  • amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
  • pellets were resuspended in buffer (5 mM Tris-HCl pH 7.5), homogenized with a teflon homogenizer and centrifuged (14000 xg, 20 min) to yield pellets which were referred to as crude membrane fractions.
  • the obtained pallets were stored at -70°C until use.
  • reaction mixture was extracted with ethyl acetate, and the organic layer was washed successively with water, and aqueous sodium hydrogencarbonate solution, 0.5N hydrochloric acid, water and an aqueous sodium
  • the object compound was obtained according to a similar manner to to that of Preparation 13.
  • the object compound was obtained according to a similar manner to to that of Preparation 25.
  • the object compound was obtained according to a similar manner to to that of Preparation 17.
  • the object compound was obtained according to a similar manner to to that of Preparation 29.
  • the object compound was obtained according to a similar manner to to that of Preparation 30 and used to the next reaction without purification.
  • the object compound was obtained according to a similar manner to to that of Preparation 5.
  • the object compound was obtained according to a similar manner to to that of Preparation 28 and used to the next reaction without purification.
  • the object compound was obtained according to a similar manner to to that of Preparation 29.
  • the object compound was obtained according to a similar manner to to that of Preparation 13.
  • the object compound was obtained according to a similar manner to to that of Preparation 17.
  • reaction mixture was poured into water (150 ml) and the pH was adjusted to 8 with sodium hydrogen carbonate solution.
  • the product was extracted with ethyl acetate and the organic layer was washed sodium hydrogen carbonate
  • reaction mixture was extracted with ethyl acetate and the organic layer was washed successively with an aqueous sodium hydrogencarbonate solution, water, 0.5N hydrochloric acid, water, and an aqueous sodium chloride solution, and dried over magnesium sulfate.
  • reaction mixture was washed successively with water, diluted sodium hydrogencarbonate solution, 0.5N hydrochloric acid and brine, and dried over magnesium sulfate. After evaporation, the crude material was purifried on a silica-gel column (80g) eluting with a mixed solvent of chloroform and methanol(from 98:8 to 96.5:3.5) to give
  • Example 10 The object compounds were obtained according to a similar manner to to that of Example 10.
  • the object compound was obtained according to a similar manner to to that of Preparation 19.
  • the object compound was obtained according to a
  • the object compound was obtained according to a

Abstract

Composés pouvant être représentés par la formule générale (I), dans laquelle R1 est un alkyle inférieur, etc., R2 est de l'hydrogène, etc., R3 est de l'hydrogène, etc., R4 est un alkyle inférieur, etc., R5 est un aralkyle inférieur, etc., A est un résidu d'aminoacide; et Y est une liaison, etc. Les composés (I) visés ici, et leurs sels acceptables du point de vue pharmaceutique ont des effets pharmacologiques tels que des effets antitachykininiques, notamment antagonistes de la substance P, et antineurokininiques A ou B.
EP92913210A 1991-06-19 1992-06-18 Peptides antagonistes de la tachykonine Withdrawn EP0590152A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9113219 1991-06-19
GB919113219A GB9113219D0 (en) 1991-06-19 1991-06-19 Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
PCT/JP1992/000780 WO1992022569A1 (fr) 1991-06-19 1992-06-18 Peptides antagonistes de la tachykonine

Publications (1)

Publication Number Publication Date
EP0590152A1 true EP0590152A1 (fr) 1994-04-06

Family

ID=10696937

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92913210A Withdrawn EP0590152A1 (fr) 1991-06-19 1992-06-18 Peptides antagonistes de la tachykonine

Country Status (4)

Country Link
EP (1) EP0590152A1 (fr)
JP (1) JPH07503701A (fr)
GB (1) GB9113219D0 (fr)
WO (1) WO1992022569A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
WO2007011820A2 (fr) 2005-07-15 2007-01-25 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
WO2007093827A1 (fr) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac)
WO2009002495A1 (fr) 2007-06-27 2008-12-31 Merck & Co., Inc. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
EP2336120A1 (fr) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
WO2012018754A2 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
WO2012027236A1 (fr) 2010-08-23 2012-03-01 Schering Corporation Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012145471A1 (fr) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
WO2014085216A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions et procédés pour traiter le cancer
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP4079856A1 (fr) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
DE59309867D1 (de) * 1992-09-03 1999-12-16 Boehringer Ingelheim Pharma Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE4243496A1 (de) * 1992-09-03 1994-03-10 Boehringer Ingelheim Kg Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
WO1995000536A1 (fr) * 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Compose a base de peptides
FR2719312B1 (fr) * 1994-04-28 1996-06-14 Adir Nouveau pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
KR100362620B1 (ko) 1994-08-25 2003-02-14 메렐 파마슈티칼스 인크. 알레르기성질환치료에유용한치환된피페리딘,이를포함하는약제학적조성물및이의제조방법
AU3993795A (en) * 1994-12-02 1996-06-19 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for prevention and/or treatment of no-mediated diseases
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
ES2224164T3 (es) * 1995-04-13 2005-03-01 Aventis Pharmaceuticals Inc. Nuevos derivados de piperazina sustituida que tienen actividad como antagonistas de los receptores de taququinina.
DE19541283A1 (de) * 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
IT1304898B1 (it) * 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
CA2362290A1 (fr) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Nouveaux derives amide secretagogues de l'hormone de croissance
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
JP3673711B2 (ja) 1999-12-27 2005-07-20 キヤノン株式会社 ポリヒドロキシアルカノエートおよび微生物を利用するその製造方法
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
JP2008546765A (ja) * 2005-06-20 2008-12-25 アストラゼネカ アクチボラグ （アルコキシカルボニルアミノ）−アルキルスルホネートの製造方法
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP2514751A1 (fr) 2005-11-15 2012-10-24 Vertex Pharmaceuticals, Inc. Azaindazoles utiles en tant qu'inhibiteurs de kinases
CA2664113C (fr) 2006-09-22 2013-05-28 Merck & Co., Inc. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
CA2682727C (fr) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Derive d'indoledione
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
EP2729147B1 (fr) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Antagonistes des récepteurs nk-1 pour traiter une néovascularisation cornéenne
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
EP4117673A1 (fr) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Traitement d'une déficience en cellules souches

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3226241A1 (de) * 1982-07-14 1984-01-26 Basf Ag, 6700 Ludwigshafen N-acylderivate von peptiden, ihre herstellung und verwendung bei der bekaempfung von krankheiten und mittel dafuer
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9222569A1 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123182A2 (fr) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Sulfones de cyclohexyle pour le traitement du cancer
WO2007011820A2 (fr) 2005-07-15 2007-01-25 Amr Technology, Inc. Tetrahydrobenzazepines substituees par aryle et heteroaryle, et leur utilisation pour bloquer la reabsorption de la noradrenaline, de la dopamine, et de la serotonine
WO2007093827A1 (fr) 2006-02-15 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dérivés de trifluoroéthanone substitués par thiophène et thiazole en tant qu'inhibiteurs d'histone désacétylase (hdac)
EP2336120A1 (fr) 2007-01-10 2011-06-22 Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. Combinaisons contenant indazoles à substitution amide utilisés comme inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
EP2805945A1 (fr) 2007-01-10 2014-11-26 MSD Italia S.r.l. Indazoles substitués d'amide en tant qu'inhibiteurs PARP de poly(ADP-ribose)polymérase
EP3103791A1 (fr) 2007-06-27 2016-12-14 Merck Sharp & Dohme Corp. Dérivés de4-carboxybenzylamino utilisés comme inhibiteurs de l'histone désacétylase
WO2009002495A1 (fr) 2007-06-27 2008-12-31 Merck & Co., Inc. Dérivés de 4-carboxybenzylamino utilisés en tant qu'inhibiteurs de l'histone désacétylase
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
WO2010132442A1 (fr) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation
WO2011046771A1 (fr) 2009-10-14 2011-04-21 Schering Corporation Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés
WO2012018754A2 (fr) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
EP3330377A1 (fr) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Inhibition à médiation par interférence arn de caténine (protéine associée à cadhérine), expression du gène bêta 1 (ctnnb1) à l'aide de petit acide nucléique interférent (sian)
EP4079856A1 (fr) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
WO2012027236A1 (fr) 2010-08-23 2012-03-01 Schering Corporation Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
EP3327125A1 (fr) 2010-10-29 2018-05-30 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012145471A1 (fr) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
WO2014085216A1 (fr) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Compositions et procédés pour traiter le cancer
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5

Also Published As

Publication number Publication date
GB9113219D0 (en) 1991-08-07
WO1992022569A1 (fr) 1992-12-23
JPH07503701A (ja) 1995-04-20

Similar Documents

Publication Publication Date Title
EP0590152A1 (fr) Peptides antagonistes de la tachykonine
EP0394989B1 (fr) Composés peptidiques, leur préparation et médicaments les renfermant
CA2032864C (fr) Composes peptidiques, procede de fabrication et composition pharmaceutique contenant lesdits composes
AU647534B2 (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5633232A (en) Tachykinin antagonist dipeptides
US5187156A (en) Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
WO1993014113A1 (fr) Peptides avec action antagoniste sur la tachykinine
EP0515681A1 (fr) Compose peptidique
JP2606528B2 (ja) 新規ペプチド化合物またはその塩類
WO1995000536A1 (fr) Compose a base de peptides
US5654400A (en) Process for making peptide compounds having tachykinin antagonistic activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19960206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960928